Coiled Therapeutics, previously Roquefort Therapeutics, has completed the acquisition of the exclusive worldwide licence to AO-252 and admitted its shares to trading on the AIM Market of the London Stock Exchange.  Admission follows a successful fundraise of £8.5 ($11.3) million through the issue of 85,000,000 New Ordinary Share with institutional investors.  The company has now […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!